Filing Flows › PTC Therapeutics (PTCT) › Q1 2025
PTC Therapeutics (PTCT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
PTC Therapeutics (PTCT) reported revenue of $1.2B for the first quarter 2025 (Q1 2025), +460% from a year earlier and +452% from the quarter before. Operating margin was 82.5%, net earnings $867M (73.7% of revenue).
PTC Therapeutics, Q1 2025: revenue $1.2B (+460% year over year), operating margin 82.5%, net earnings $867M, operating cash flow $870M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2B | +452% | +460% |
| Operating profit | $970M | — | — |
| Net earnings | $867M | — | — |
| Operating cash flow | $870M | — | 12× |
| Free cash flow | $868M | — | 14× |
What changed
Revenue was $1.2B in Q1 2025, up 460% year over year and up 452% from the previous quarter. Collaboration and license revenue was the largest line at 84% of revenue. Royalty revenue added $0.01B year over year (up 17%), 1% of the total change. Net product revenue declined 14%.
Operating profit was $1.0B, a 82.5% margin (up 104.1 points year over year). Total costs fell 19% while revenue rose 460%. The fastest-growing cost line was SG&A (+10%). Net earnings were $0.87B. The effective tax rate was 6.8%.
Operating cash flow was $0.87B (up 1130% year over year), 100% of net earnings. Non-cash charges added back $0.01B of depreciation and amortization and $0.02B of share-based compensation. Capital expenditures of $1.7M left free cash flow of $0.87B.
Questions
What was PTC Therapeutics' revenue in the first quarter 2025?
PTC Therapeutics (PTCT) reported revenue of $1.2B for the first quarter 2025 (Q1 2025), +460% from a year earlier and +452% from the quarter before.
Was PTC Therapeutics profitable in the first quarter 2025?
Operating profit was $970M (82.5% of revenue) and net earnings $867M.
Source: PTC Therapeutics 10-Q on SEC EDGAR.